Wall Street Zen cut shares of Cybin (NASDAQ:HELP – Free Report) from a sell rating to a strong sell rating in a research note released on Saturday morning,Wall Street Zen reports.
HELP has been the subject of a number of other research reports. TD Cowen upped their price target on Cybin from $8.00 to $62.00 and gave the stock a “buy” rating in a research report on Thursday, August 20th. Barclays started coverage on shares of Cybin in a report on Friday, September 18th. They issued an “overweight” rating and a $35.00 price objective on the stock. Finally, Wells Fargo & Company boosted their price objective on shares of Cybin from $16.00 to $22.00 and gave the stock an “overweight” rating in a research report on Thursday, October 22nd. Six investment analysts have rated the stock with a Buy rating. According to MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $47.33.
Check Out Our Latest Analysis on HELP
Cybin Price Performance
Cybin (NASDAQ:HELP – Get Free Report) last announced its earnings results on Friday, August 14th. The company reported ($0.91) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.80) by ($0.11). Equities analysts expect that Cybin will post -2.95 EPS for the current year.
Insider Buying and Selling
In related news, insider Eric H. L. So bought 100,000 shares of the stock in a transaction that occurred on Tuesday, September 8th. The shares were acquired at an average price of $12.39 per share, with a total value of $1,239,000.00. Following the completion of the transaction, the insider owned 4,465,014 shares in the company, valued at $55,321,523.46. The trade was a 2.29% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Paul Glavine bought 100,000 shares of the company’s stock in a transaction that occurred on Tuesday, September 8th. The shares were bought at an average price of $12.47 per share, for a total transaction of $1,247,000.00. Following the acquisition, the insider directly owned 4,271,252 shares of the company’s stock, valued at $53,262,512.44. This represents a 2.40% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders have purchased 688,000 shares of company stock worth $8,422,830 over the last 90 days. 15.00% of the stock is currently owned by insiders.
Institutional Inflows and Outflows
A number of hedge funds have recently bought and sold shares of HELP. Royce & Associates LP acquired a new position in shares of Cybin during the 3rd quarter worth approximately $5,286,000. Pale Fire Capital SE bought a new stake in shares of Cybin during the 2nd quarter worth approximately $1,015,000. ACT Capital Partners L.P. acquired a new stake in shares of Cybin in the 3rd quarter valued at approximately $1,659,000. WealthPlan Investment Management LLC acquired a new stake in shares of Cybin in the 3rd quarter valued at approximately $1,272,000. Finally, Farther Finance Advisors LLC boosted its holdings in shares of Cybin by 927.4% in the 3rd quarter. Farther Finance Advisors LLC now owns 22,818 shares of the company’s stock valued at $280,000 after buying an additional 20,597 shares during the last quarter. 17.94% of the stock is currently owned by institutional investors.
Cybin Company Profile
Cybin Inc is a clinical-stage biopharmaceutical company focused on developing psychedelic-based therapeutics for mental health conditions. The company’s research programs are designed to address disorders such as major depressive disorder and other conditions where existing treatments may not provide adequate relief.
Cybin’s development platform has included investigational compounds such as CYB003, a deuterated psilocybin analog being studied for depression, and CYB004, an investigational N,N-dimethyltryptamine (DMT) formulation being evaluated for potential use in mental health treatment.
Further Reading
- Five stocks we like better than Cybin
- Wall Street May Be Making a Big Mistake With monday.com Stock
- Are These 2 Mid-Cap Growth Stocks Worth the Risk?
- Oklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next?
- Cloudflare’s 20% Sell-Off May Have Created an Opening for Investors
Receive News & Ratings for Cybin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cybin and related companies with MarketBeat.com's FREE daily email newsletter.
